Q32 Bio Inc (QTTB)
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologics aimed at restoring healthy immune balance in autoimmune and inflammatory diseases linked to immune dysfunction. Its lead program, Bempikibart (ADX-914), is a fully human monoclonal antibody targeting interleukin-7 receptor alpha; it has completed Phase 2a clinical testing and is being evaluated for conditions including atopic dermatitis and alopecia areata. The company is also advancing ADX-096, a C3d mAb-CR1 fusion protein intended for ophthalmologic applications, along with other C3d-based fusion proteins and nanobody programs designed for tissue-targeted complement inhibition. Q32 Bio was founded in 2017 and is headquartered in Waltham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-QTTB
|
$16.08
|
8.9% Upside
|
Fair
|
$38.75
|
162.4% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
7.5x
|
5.4x
|
4.6x
|
255 M
|
212 M
|
5.1%
|
—
|
7.0
|
—
|
-82.4%
|
